Okada

Atsushi Okada, MD, PhD

Valve Science Center International Scholar

Dr. Atsushi Okada joined MHIF from the National Cerebral and Cardiovascular Center (NCVC) in Osaka, Japan. Dr. Okada received his medical degree from Chiba University School of Medicine at 2009 and completed residency training in Teine Keijinkai Hospital in Sapporo, Japan. He started his cardiology fellowship at NCVC in 2012 and has been working as a cardiology attending physician ever since.

His primary interest is in heart failure and non-pharmacological treatments, with a main focus on valvular heart disease and cardiomyopathies, including a recent interest in cardiac amyloidosis. He is a certified operator for TAVR and MitraClip, which includes experience with Sapien XT, Sapien 3, all corevalve series from the CoreValve to EvolutPRO+, MitraClip G2/G4 devices, and some experience with Portico/Navitor. As a trial member, he also has some experiences with TriClip, mitral valve in valve, paravalvular leak closure, Corvia Reduce LAP II, and Medtronic Intrepid valve. Regarding cardiac amyloidosis, he is a certified prescriber of tafamidis (Vyndaqel) of the Japanese Circulation Society, and was also in charge of multiple ongoing medical trials for ATTR-CM.

At MHIF, he is looking forward to working with Dr. Bapat and the Valve Science Center physicians to enhance his experience with new treatments and devices.

Back to Valve Team Back to Current Scholars
 

Okada
Give the Gift of Hope
4 photos of families smiling

The Minneapolis Heart Institute Foundation® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

blue background
Triclip team

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.